Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Patterns of Primary Biliary Cholangitis: Comparison Between Two European Case Series

Author(s): Ludovico Abenavoli*, Anna Caterina Procopio, Pietro Cinaglia, Christian Zanza, Claudio Delle Grazie, Yaroslava Longhitano, Pavla Libicherova and Francesco Luzza

Volume 17, Issue 2, 2022

Published on: 26 August, 2022

Page: [136 - 142] Pages: 7

DOI: 10.2174/1574887117666220617095856

Price: $65

Abstract

Background: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of the intrahepatic bile ducts, followed by fibrous substitution of the ducts and potential evolution in cirrhosis. The geographical disparity in the prevalence of PBC suggests a possible role of environmental factors in developing the disease. We analyzed two groups of patients with different geographical prevalence.

Methods: This study concerned the analysis of 14 Caucasian patients in two groups: ten patients enrolled in the Digestive Diseases Unit, University of Catanzaro (Italy), and four patients enrolled in the Department of Hepatology, University Hospital Kràlovskè Vinohrady of Prague (Czech Republic). The statistical analysis was performed using the software IBM SPSS (v. 20, Windows).

Results: The Italian group showed a statistically significant difference in the total bilirubin values at diagnosis and during the last control (0.74±0.267 vs. 0.56±0.246; p-value: 0.013). Moreover, the comparison between the two groups showed a statistically significant difference in the serum albumin values at the time of the last control (4.6±0.231 vs. 4.15±0.532; p-value: 0.048).

Conclusion: Our data indicate an effective difference in the onset and clinical presentation between our two groups. More epidemiologic, prospective, and multicenter research projects are warranted to advance PBC knowledge in Europe.

Keywords: Liver disease, autoimmunity, therapy, ursodeoxycholic acid, primary biliary cholangitis, biliary epithelial injury.

« Previous Next »
[1]
Gao, L.; Wang, L.; Woo, E. Clinical management of primary biliary cholangitis-strategies and evolving trends. Clin. Rev. Allergy Immunol., 2020, 59(2), 175-194.
[http://dx.doi.org/10.1007/s12016-019-08772-7] [PMID: 31713023]
[2]
Bossen, L.; Rebora, P.; Bernuzzi, F. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver Int., 2020, 40(6), 1408-1414.
[http://dx.doi.org/10.1111/liv.14466] [PMID: 32279422]
[3]
Lindor, K.D.; Gershwin, M.E.; Poupon, R.; Kaplan, M.; Bergasa, N.V.; Heathcote, E.J. Primary biliary cirrhosis. Hepatology, 2009, 50(1), 291-308.
[http://dx.doi.org/10.1002/hep.22906] [PMID: 19554543]
[4]
Talwalkar, J.A.; Lindor, K.D. Primary biliary cirrhosis. Lancet, 2003, 362(9377), 53-61.
[http://dx.doi.org/10.1016/S0140-6736(03)13808-1] [PMID: 12853201]
[5]
EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 2017, 67(1), 145-172.
[http://dx.doi.org/10.1016/j.jhep.2017.03.022] [PMID: 28427765]
[6]
Marzioni, M.; Bassanelli, C.; Ripellino, C.; Urbinati, D.; Alvaro, D. Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. Dig. Liver Dis., 2019, 51(5), 724-729.
[http://dx.doi.org/10.1016/j.dld.2018.11.008] [PMID: 30584000]
[7]
Selmi, C.; Mayo, M.J.; Bach, N. Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology, 2004, 127(2), 485-492.
[http://dx.doi.org/10.1053/j.gastro.2004.05.005] [PMID: 15300581]
[8]
Shin, S.; Moh, I.H.; Woo, Y.S. Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis. World J. Gastroenterol., 2017, 23(39), 7191-7197.
[http://dx.doi.org/10.3748/wjg.v23.i39.7191] [PMID: 29093628]
[9]
Cheung, A.C.; LaRusso, N.F.; Gores, G.J.; Lazaridis, K.N. Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis. Semin. Liver Dis., 2017, 37(2), 159-174.
[http://dx.doi.org/10.1055/s-0037-1603324] [PMID: 28564724]
[10]
Moteki, S.; Leung, P.S.; Dickson, E.R. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology, 1996, 23(3), 436-444.
[http://dx.doi.org/10.1002/hep.510230307] [PMID: 8617422]
[11]
Invernizzi, P.; Selmi, C.; Poli, F. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48(6), 1906-1912.
[http://dx.doi.org/10.1002/hep.22567] [PMID: 19003916]
[12]
Lammert, C.; Nguyen, D.L.; Juran, B.D. Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig. Liver Dis., 2013, 45(7), 589-594.
[http://dx.doi.org/10.1016/j.dld.2013.01.028] [PMID: 23490343]
[13]
Prince, M.I.; Ducker, S.J.; James, O.F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut, 2010, 59(4), 508-512.
[http://dx.doi.org/10.1136/gut.2009.184218] [PMID: 20332522]
[14]
Gershwin, M.E.; Selmi, C.; Worman, H.J. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology, 2005, 42(5), 1194-1202.
[http://dx.doi.org/10.1002/hep.20907] [PMID: 16250040]
[15]
Bergasa, N.V. Pruritus and fatigue in primary biliary cirrhosis. Clin. Liver Dis., 2003, 7(4), 879-900.
[http://dx.doi.org/10.1016/S1089-3261(03)00105-3] [PMID: 14594135]
[16]
Kaplan, M.M.; Gershwin, M.E. Primary biliary cirrhosis. N. Engl. J. Med., 2005, 353(12), 1261-1273.
[http://dx.doi.org/10.1056/NEJMra043898] [PMID: 16177252]
[17]
Talwalkar, J.A.; Souto, E.; Jorgensen, R.A.; Lindor, K.D. Natural history of pruritus in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol., 2003, 1(4), 297-302.
[http://dx.doi.org/10.1016/S1542-3565(03)00134-4] [PMID: 15017671]
[18]
Nakamura, T.; Higashi, S.; Tomoda, K.; Tsukano, M.; Sugi, K. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin. Rheumatol., 2007, 26(4), 596-600.
[http://dx.doi.org/10.1007/s10067-005-0178-x] [PMID: 16496080]
[19]
Purohit, T.; Cappell, M.S. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J. Hepatol., 2015, 7(7), 926-941.
[http://dx.doi.org/10.4254/wjh.v7.i7.926] [PMID: 25954476]
[20]
Corpechot, C.; Abenavoli, L.; Rabahi, N. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology, 2008, 48(3), 871-877.
[http://dx.doi.org/10.1002/hep.22428] [PMID: 18752324]
[21]
Bosch, A.; Dumortier, J.; Maucort-Boulch, D. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J. Hepatol., 2015, 63(6), 1449-1458.
[http://dx.doi.org/10.1016/j.jhep.2015.07.038] [PMID: 26282232]
[22]
Corpechot, C.; Chazouillères, O.; Rousseau, A. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N. Engl. J. Med., 2018, 378(23), 2171-2181.
[http://dx.doi.org/10.1056/NEJMoa1714519] [PMID: 29874528]
[23]
Paumgartner, G.; Beuers, U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology, 2002, 36(3), 525-531.
[http://dx.doi.org/10.1053/jhep.2002.36088] [PMID: 12198643]
[24]
Lammers, W.J.; van Buuren, H.R.; Hirschfield, G.M. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study. Gastroenterology, 2014, 147(6), 1338-49.e5.
[http://dx.doi.org/10.1053/j.gastro.2014.08.029] [PMID: 25160979]
[25]
Wilde, A.B.; Lieb, C.; Leicht, E. Real-World clinical management of patients with primary biliary cholangitis-a retrospective multicenter study from germany. J. Clin. Med., 2021, 10(5), 1061.
[http://dx.doi.org/10.3390/jcm10051061] [PMID: 33806503]
[26]
Alvaro, D.; Carpino, G.; Craxi, A.; Floreani, A.; Moschetta, A.; Invernizzi, P. Primary biliary cholangitis management: Controversies, perspectives and daily practice implications from an expert panel. Liver Int., 2020, 40(11), 2590-2601.
[http://dx.doi.org/10.1111/liv.14627] [PMID: 32757367]
[27]
Corpechot, C.; Poupon, R.; Chazouillères, O. New treatments/targets for primary biliary cholangitis. JHEP Rep, 2019, 1(3), 203-213.
[http://dx.doi.org/10.1016/j.jhepr.2019.05.005] [PMID: 32039371]
[28]
Pellicciari, R.; Fiorucci, S.; Camaioni, E. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45(17), 3569-3572.
[http://dx.doi.org/10.1021/jm025529g] [PMID: 12166927]
[29]
Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov., 2008, 7(8), 678-693.
[http://dx.doi.org/10.1038/nrd2619] [PMID: 18670431]
[30]
Beuers, U.; Trauner, M.; Jansen, P.; Poupon, R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J. Hepatol., 2015, 62(1)(Suppl.), S25-S37.
[http://dx.doi.org/10.1016/j.jhep.2015.02.023] [PMID: 25920087]
[31]
Abenavoli, L.; Procopio, A.C.; Fagoonee, S. Primary biliary cholangitis and bile acid farnesoid X receptor agonists. Diseases, 2020, 8(2), E20.
[http://dx.doi.org/10.3390/diseases8020020] [PMID: 32532037]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy